Executive Managment Team
Colin Hill
C.E.O., President, Chairman & Co-Founder
Colin Hill brings years of hands-on scientific
experience to his role, with expertise in the areas of
computational physics and systems biology. Hill is a
frequent speaker at international scientific and
industry conferences and has appeared in numerous
publications and television segments including The Wall
Street Journal, CNBC Morning Call, Nature, Wired, and
the Economist. In 2004, Hill was named to MIT
Technology Review's TR100 list of the top innovators in
the world under the age of 35. He graduated from
Virginia Tech with a degree in physics and earned
master's degrees in physics from McGill University and
Cornell University.
Iya Khalil, Ph.D.
Executive Vice President and Co-Founder
Iya Khalil oversees the application of the company's
disease and drug simulation technology in alliances
with pharmaceutical and biotech companies. A frequent
speaker at industry events and conferences, she has
extensive experience in reverse engineering and forward
simulations of large-scale genetic and biochemical
networks. Dr. Khalil is an inventor on a number of
pending patents and has published multiple articles on
in silico technologies applied to drug discovery and
development. Prior to joining GNS, she worked at
Cornell University, University of Washington and Abbott
Labs. Dr. Khalil holds a B.S. in physics from the
University of Washington and a Ph.D. in physics from
Cornell University.
Jim Collins
Chief Scientific Officer
Jim Collins serves as GNS's Chief Scientific
Officer and the co-chair of GNS's Scientific Advisory
Board. He is a University Professor, Professor of
Biomedical Engineering, and the Co-Director at Center
for BioDynamics at Boston University, and was a founder
of Cellicon Biotechnologies. Professor Collins'
research focuses on developing and implementing
techniques and concepts from nonlinear dynamics and
statistical physics to study and improve the function
of physiological and biological systems. Professor
Collins has received a number of awards, including a
Rhodes Scholarship, the American Society of
Biomechanics Young Scientist Award, and being selected
for Technology Review's TR100 - 100 top young
innovators in science and technology. He has published
over 100 peer-reviewed journal articles and 200
conference abstracts. Professor Collins has received
research support from the National Institutes of
Health, the National Science Foundation, the Whitaker
Foundation, the Department of Energy, the Department of
Education, the Department of Veterans Affairs, and the
Office of Naval Research. In 2003, Professor Collins
received a MacArthur Fellowship (a "Genius Award"), and
in 2005 he was selected for the Scientific American 50
- top 50 outstanding leaders in science and technology.
Thomas Neyarapally
Vice President, Corporate Strategy and Intellectual Property
Thomas Neyarapally spearheads and implements the
strategic vision for the expansion, protection and
monetization of Gene Network Sciences' intellectual
property. Before joining GNS, Neyarapally served as an
associate in the New York office of the intellectual
property firm Frommer, Lawrence & Haug LLP, where he
focused on transactional, product development, and
Hatch-Waxman litigation matters for clients in the
pharmaceutical and biotech industries. Neyarapally
previously was an associate in the corporate department
at Chadbourne & Parke, LLP, and held the position of
analyst at Arthur D. Little. Neyarapally holds a J.D.
and an M.B.A. from Cornell University. While attending
Cornell's Johnson Graduate School of Management, he
served as a partner at BR Ventures, the only
student-run venture capital firm in the United States.
Neyarapally graduated from the University of
Connecticut with a B.S. in chemical engineering.
Jeffrey Fox, Ph.D.
Vice President, Cardiovascular Research
One of the founding researchers at Gene Network
Sciences, Jeffrey Fox oversees the creation and
validation of GNS cardiac technology. Dr. Fox's team
consists of computational scientists who develop
methods for integrating heterogeneous data to predict
the effects of compounds on the heart's
electrocardiogram. Dr. Fox has been awarded multiple
NIH grants, including four SBIR Grants totaling $2
million and a $2 million Bioengineering Research Grant
in partnership with Cornell University and UCSD. He
holds a B.S. in physics from the Ohio State University
and a Ph.D. in physics from Cornell University.